obecabtagene autoleucel
Selected indexed studies
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. (N Engl J Med, 2024) [PMID:39602653]
- Obecabtagene Autoleucel: First Approval. (Mol Diagn Ther, 2025) [PMID:39888581]
- Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion? (Expert Rev Hematol, 2025) [PMID:40550480]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (2024) pubmed
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. (2024) pubmed
- Obecabtagene Autoleucel: First Approval. (2025) pubmed
- Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion? (2025) pubmed
- Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia. (2025) pubmed
- PMID:41538472 (2025) pubmed
- In brief: Obecabtagene autoleucel (Aucatzyl) - another CAR-T cell immunotherapy for ALL. (2024) pubmed
- Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. (2025) pubmed
- [Obecabtagene autoleucel (Obe-cel) in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia]. (2026) pubmed
- Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. (2026) pubmed